Glycine is an amino acid and one of the main inhibitory neurotransmitters in the brain. Glycine normalizes and activates protective inhibition processes in the central nervous system, reduces psycho-emotional stress, and increases mental performance.

Glycine has glycine and GABAergic effects, alpha1-adrenergic blocking; also regulates glutamate (NMDA) receptor activity.

The drug has the following properties:

• reduces psycho-emotional stress, irritability, tendency to conflicts; improves social adaptation;
• improves mood;
• facilitates falling asleep and normalizes sleep;
• increases mental efficiency;
• reduces vegetative-vascular disorders (including those during menopause);
• reduces the severity of brain disorders in ischemic stroke and traumatic brain injury;
• reduces the toxic effects of alcohol and other central nervous system depressants.

Pharmacokinetics: easily penetrates most biological fluids and body tissues, as well as the brain; metabolized into water and carbon dioxide; accumulation in the body does not occur.

Trade name: Glycine

International Nonproprietary Name: Glycine.

Dosage form: sublingual tablets.

Composition in 1 tablet: microencapsulated glycine (expressed as active substance glycine - 100 mg), auxiliary substances: methyl cellulose - 1 mg, magnesium stearate - 1 mg.

Appearance: round flat cylindrical tablets, white or off-white with marble elements, beveled and grooved.

Therapeutic category: Metabolism drug.